New hope against deadly molds? early trial cut short
NCT ID NCT04240886
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a drug called fosmanogepix in 21 adults with invasive mold infections (like Aspergillus or rare molds) who had few other options. The trial was stopped early, so we have limited data on how well it works or its safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fosmanogepix (also called APX001)
What this could lead to
If successful, this could provide a new treatment option for people with hard-to-treat invasive mold infections who cannot use standard therapies.
What could go wrong
This was a small, early-phase trial that was terminated, so results are limited. The drug may not prove effective or safe in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INVASIVE FUNGAL INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU UCL Namur - Mont- Godinne University Hospital - Intensive Care Unit
Yvoir, 5530, Belgium
-
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
Duarte, California, 91010, United States
-
Cliniques Universitaires de Bruxelles Hôpital Erasme - Department of Infectious Diseases
Brussels, 1070, Belgium
-
Duke Department of Pharmacy/Investigational Drug Service (IDS)
Durham, North Carolina, 27710, United States
-
Duke Medicine Pavilion
Durham, North Carolina, 27710, United States
-
Duke University Medical Center (Duke South Clinic)
Durham, North Carolina, 27710, United States
-
Duke University Medical Center(Duke Hospital)
Durham, North Carolina, 27710, United States
-
IP Address : City of Hope Investigational Drug Services (IDS)
Duarte, California, 91010, United States
-
Klinikum Neuperlach, Klinik fur Hamatologie und Onkologie
München, Bavaria, 81737, Germany
-
Pharmacy
Haifa, 3109601, Israel
-
Pharmacy
Ramat Gan, 5262160, Israel
-
Rambam Medical Center
Haifa, 3109601, Israel
-
Sheba Medical Center, Tel Hashomer
Ramat Gan, 5262160, Israel
-
UZ Leuven - Department of Haematology
Leuven, 3000, Belgium
-
Universitätsmedizin der Johannes Gutenberg-Universität Mainz III
Mainz, 55131, Germany